This week we cover a study that identified factors associated with strong antibody responses to COVID; How convalescent plasmas benefits may be limited; A nasal spray to treat diabetic gastroparesis; Recommendations for colorectal cancer screening; And a new treatment approved for dry eye disease. And of course, movie trivia!
Gimoti, a dopamine-2 (D2) antagonist, is a nasal spray formulation of metoclopramide.
To evaluate the association, the study authors utilized healthcare databases from Ontario, Canada to identify adults 66 years of age and older with no history of AF who filled at least 1 prescription for levothyroxine.
As insulin pens often have similar appearances and are not labeled for dispensing as individual units, the carton helps both healthcare professionals and patients distinguish between the products.
Ertugliflozin is noninferior to placebo for the primary end point of major adverse cardiovascular events.
The C0311002 study compared the patient perception of treatment burden with use of somatrogon to somatropin in 87 children aged 3 to 17 years with GHD.
The designation was granted based on results from the phase 3 DAPA-CKD trial, which was stopped early due to “overwhelming efficacy”.
The propensity score-matched longitudinal study aimed to compare the efficacy of generic and brand-name formulations of levothyroxine in achieving and maintaining target thyrotropin levels.
Alkindi® Sprinkle (hydrocortisone) will be available as 0.5mg, 1mg, 2mg, and 5mg oral granules.
Risks for MACE, MI, cardiovascular death, heart failure, all-cause mortality lower versus DPP-4 inhibitors
